UNSPSC 51141509: Vigabatrin

This classification denotes an anticonvulsant agent with the molecular formula C6H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GR120KRT6K, chemically known as 5-hexenoic acid, 4-amino- but generally known as vigabatrin, which bears US NIH Compound Identifier 5665. European Medicines Agency schedules Vigabatrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00048MIG.

UNSPSC 51141509 Vigabatrin, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The single recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS—actually solicits naloxone and drug deactivation systems for community health support, a misalignment with vigabatrin's anticonvulsant drug classification. State and local governments procuring under this code would typically purchase vigabatrin for public health programs, corrections facilities, or clinical settings; however, current market signals do not reflect active demand for vigabatrin specifically through state and local competitive bidding channels.

The Seminole County opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, represents the only recent record available for this code and reflects a code-tagging error rather than vigabatrin procurement. The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, Florida, with all shipping and delivery costs included in vendor proposals. The contract included a two-year initial term with a one-year renewal option and required E-Verify compliance, drug-free workplace certification, and specific insurance coverages. Potential FEMA funding introduced additional federal compliance layers including the Clean Air Act and Federal Water Pollution Control Act. The code shows no geographic spread or repeat issuing bodies; no other state or local jurisdictions appear in the recent-opportunities record for vigabatrin procurement.